Search results for "Pori"

showing 10 items of 761 documents

Failure of sustained engraftment after non-myeloablative conditioning with low-dose TBI and T cell-reduced allogeneic peripheral stem cell transplant…

2001

We investigated whether a T cell-reduced allogeneic stem cell transplant (SCT) with minimal conditioning and subsequent donor lymphocyte infusions (DLI) could reduce the incidence and severity of GVHD while retaining stable engraftment. Five patients with hematological malignancies (three MM, one CLL, one Chediak-Higashi syndrome) were conditioned with TBI (200 cGy). One patient additionally received fludarabine (120 mg/m(2)). CsA and mofetyl-mycophenolate (MMF) were administered to prevent GVHD. All patients were grafted with >3 x 10(6)/kg highly purified CD34(+) cells together with 2 x 10(6)/kg CD3(+) cells (three patients) or 1 x 10(5)/kg CD3(+) cells (two patients). Quick hematopoietic …

AdultMaleTime FactorsLymphocyte TransfusionT-LymphocytesT cellLymphocyteChronic lymphocytic leukemiamedicine.medical_treatmentHematopoietic stem cell transplantationLymphocyte DepletionFatal OutcomemedicineHumansTransplantation HomologousTreatment FailureTransplantation ChimeraTransplantationbusiness.industryHematopoietic Stem Cell TransplantationHematologyMiddle AgedMycophenolic Acidmedicine.diseaseLeukemia Lymphocytic Chronic B-CellPeripheral stem cell transplantationFludarabineTransplantationmedicine.anatomical_structureHematologic NeoplasmsLymphocyte TransfusionImmunologyCyclosporineFemaleChediak-Higashi SyndromeMultiple MyelomabusinessImmunosuppressive AgentsVidarabineWhole-Body IrradiationFollow-Up Studiesmedicine.drugBone Marrow Transplantation
researchProduct

Handling forces for the use of different inhaler devices.

2019

Abstract Age and comorbidities can impact on the success of handling an inhaler. In this pilot study, we assessed finger strength in 62 participants (aged 5–17 years [n = 20], 18–65 years [n = 22] and > 65 years [n = 20]) by using different types of inhalers with integrated sensors (Respimat®, Breezhaler®, Aerolizer®, Genuair®, Diskus®, Ellipta®, HandiHaler®, Turbohaler® and a pressurized metered-dose inhaler [Atrovent®]). Parameters under investigation included the spontaneous and maximum achievable force and torque required to operate devices. Satisfaction with individual inhalers, and the relationship between satisfaction and strength, were also assessed. There was a marked difference in…

AdultMalemedicine.medical_specialtyAdolescentPharmaceutical SciencePilot Projects02 engineering and technology030226 pharmacology & pharmacyFingers03 medical and health sciencesYoung Adult0302 clinical medicineAge groupsRheumatic DiseasesAdministration InhalationMedicineHumansChildAgedAged 80 and overHand Strengthbusiness.industryInhalerNebulizers and VaporizersHealthy subjectsAge FactorsRheumatic diseaseEquipment DesignMiddle Aged021001 nanoscience & nanotechnologyPatient preferenceDry-powder inhalerPatient SatisfactionCase-Control StudiesChild PreschoolPhysical therapyFemale0210 nano-technologybusinessInternational journal of pharmaceutics
researchProduct

Effects of intraocular cefotaxime on the human corneal endothelium

2001

Abstract Purpose To ascertain whether 0.4 mL of cefotaxime 0.25% applied intracamerally causes toxic alteration of the human corneal endothelium. Methods In this prospective randomized masked study, 66 patients had cataract extraction using phacoemulsification, a frown incision, and implantation of a poly(methyl methacrylate) intraocular lens. This was followed by intraocular injection of 0.4 mL of cefotaxime 0.25% or balanced salt solution (BSS®). Contact specular microscopy and photography were performed preoperatively and 1 to 4 days and 3 months postoperatively. Results In the cefotaxime group, the mean endothelial cell count was 2729 cells/mm 2 ± 474 (SD) preoperatively, 2520 ± 462 cel…

AdultMalemedicine.medical_specialtyCorneal endotheliumCefotaximeAnterior Chambermedicine.medical_treatmentCell CountIntraocular lensBalanced salt solutionCefotaximeDouble-Blind MethodLens Implantation IntraocularCorneaOphthalmologymedicineHumansProspective StudiesAgedCell SizeAntibacterial agentAged 80 and overEndophthalmitisPhacoemulsificationbusiness.industryEndothelium CornealPhacoemulsificationMiddle AgedSensory SystemsCephalosporinsEndothelial stem cellOphthalmologymedicine.anatomical_structureFemaleSurgerysense organsbusinessmedicine.drugJournal of Cataract and Refractive Surgery
researchProduct

Ciclosporin and prednisone v. prednisone in treatment of Graves' ophthalmopathy: a controlled, randomized and prospective study.

1986

Forty patients with Graves' ophthalmopathy stages III-V were divided into two groups in a random manner according to their year of birth. Group I received prednisone in decreasing dosage. Group II received prednisone at a comparable dosage and ciclosporin. Steroids were discontinued after 10 weeks in the two groups. In the patients of group II, ciclosporin was continued over 12 months. The therapeutic effect was assessed by an activity score based on subjective and objective symptoms (computerized tomography and sonography of the orbit, Hertel values, clinical findings). All signs of endocrine ophthalmopathy improved significantly in both groups (P less than 0.01 in group I; P less than 0.0…

AdultMalemedicine.medical_specialtyEye DiseasesClinical BiochemistryVisual AcuityCyclosporinsBiochemistryGastroenterologylaw.inventionGraves' ophthalmopathyPharmacotherapyRandomized controlled triallawPrednisoneInternal medicinemedicineHumansProspective StudiesProspective cohort studyClinical Trials as TopicDose-Response Relationship Drugbusiness.industryTherapeutic effectGeneral MedicineMiddle AgedCiclosporinmedicine.diseaseGraves DiseaseClinical trialEndocrinologyPrednisoneDrug Therapy CombinationFemalebusinessmedicine.drugFollow-Up StudiesEuropean journal of clinical investigation
researchProduct

Cardioprotective Effects of the Na + /H + Exchange Inhibitor Cariporide in Patients With Acute Anterior Myocardial Infarction Undergoing Direct PTCA

2000

Background —Activation of Na + /H + exchange in myocardial ischemia and/or reperfusion leads to calcium overload and myocardial injury. Experimental studies have shown that Na + /H + exchange inhibitors can attenuate Ca 2+ influx into cardiomyocytes. We therefore performed a multicenter, randomized, placebo-controlled clinical trial to test the hypothesis that inhibition of Na + /H + exchange limits infarct size and improves myocardial function in patients with acute anterior myocardial infarction (MI) treated with direct PTCA. Methods and Results —One hundred patients were randomized to receive placebo (n=51) or a 40-mg intravenous bolus of the Na + /H + exchange inhibitor cariporide (HOE…

AdultMalemedicine.medical_specialtySodium-Hydrogen Exchangersmedicine.medical_treatmentMyocardial InfarctionPlaceboGuanidinesVentricular Function LeftLesionchemistry.chemical_compoundPhysiology (medical)AngioplastyInternal medicinemedicineHumansCardioprotective AgentSulfonesMyocardial infarctionAngioplasty Balloon CoronaryAgedChemotherapybiologyCariporidebusiness.industryMyocardiumHeartMiddle Agedmedicine.diseaseTreatment OutcomechemistryAnesthesiabiology.proteinCardiologyFemaleCreatine kinasemedicine.symptomCardiology and Cardiovascular MedicinebusinessCirculation
researchProduct

Timing of quality of life improvements in psoriatic patients treated with different systemic therapies

2019

Psoriasis impacts the quality of life (QoL) by disrupting overall health and social life. Thus, the use of a QoL evaluation item is crucial in assessing a therapeutic regimen. Also, faster improvements in QoL lead to better patient compliance, but very few studies compare psoriasis traditional and biologic therapies timing. To evaluate how much different systemic therapies improve disease severity and QoL, a retrospective analysis was performed on 56 patients. Subjects were administered different drugs and their vital statistics, psoriasis area severity index (PASI) and PSOdisk were collected at baseline and after 30 days. We found a moderate correlation between PASI and PSOdisk score with …

AdultMalemedicine.medical_specialtyTime FactorsAdolescentAnti-Inflammatory AgentsDermatologySeverity of Illness IndexSocial lifeYoung Adult030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineDisease severityQuality of lifeSurveys and QuestionnairesPsoriasisInternal medicinesystemic therapiesUstekinumabmedicineHumansPsoriasisPatient complianceAgedRetrospective StudiesSkinpsoriasiAged 80 and overTherapeutic regimenbusiness.industryBiologic therapiesAdalimumabGeneral MedicineMiddle Agedmedicine.diseasehumanitiesBiological TherapyTreatment Outcomequality of life030220 oncology & carcinogenesisCyclosporineFemaleUstekinumabDermatologic AgentsbusinessFollow-Up Studiesmedicine.drug
researchProduct

A randomized trial of steroid avoidance in renal transplant patients treated with everolimus and cyclosporine

2005

In this randomized trial renal transplant recipients were treated with basiliximab, everolimus 3 mg/day, low-dose CsA. At transplantation, patients were randomized to stop steroids at the seventh day (group A) or to continue oral steroids in low doses (group B). Of the 113 patients enrolled, 65 were randomized to group A and 68 to group B. All patients were followed for 2 years. During the study 28 (43%) group A patients required reintroduced corticosteroids. One patient died, in group B. The Graft survival rate was 97% in group A and 90% in group B. There were more biopsy-proven rejections in group A (32% vs 16%; P = .044). The mean creatinine clearance was 54 +/- 21 mL/min in group A vs 5…

AdultMalemedicine.medical_specialtyTime FactorsAdolescentBasiliximabUrologyRenal functionGroup AGroup Blaw.inventionRandomized controlled triallawAdrenal Cortex HormonesHLA AntigensmedicineLiving DonorsHumansEverolimuscyclosporineAgedSirolimusTransplantationEverolimusbusiness.industryHistocompatibility TestingeverolimuMiddle Agedrenal transplantationKidney TransplantationSurgerySteroid Avoidance in Renal Transplant PatientsTransplantationRegimentrial; transplant; immunosoppressivesteroid avoidanceSurgeryFemalebusinessImmunosuppressive Agentsmedicine.drugFollow-Up Studies
researchProduct

Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell glo…

2011

Abstract Previous randomized graft-versus-host disease (GVHD)-prophylaxis trials have failed to demonstrate reduced incidence and severity of chronic GVHD (cGVHD). Here we reanalyzed and updated a randomized phase 3 trial comparing standard GVHD prophylaxis with or without pretransplantation ATG-Fresenius (ATG-F) in 201 adult patients receiving myeloablative conditioning before transplantation from unrelated donors. The cumulative incidence of extensive cGVHD after 3 years was 12.2% in the ATG-F group versus 45.0% in the control group (P < .0001). The 3-year cumulative incidence of relapse and of nonrelapse mortality was 32.6% and 19.4% in the ATG-F group and 28.2% and 33.5% in the contr…

AdultMalemedicine.medical_specialtyTime FactorsTransplantation ConditioningAdolescentmedicine.medical_treatmentImmunologyMedizinGraft vs Host DiseaseHematopoietic stem cell transplantationBiochemistryGastroenterologyDisease-Free Survivallaw.inventionRandomized controlled triallawRecurrenceInternal medicinemedicineHumansTransplantation HomologousCumulative incidenceSurvival rateAntilymphocyte SerumImmunosuppression Therapybusiness.industryIncidence (epidemiology)Hazard ratioHematopoietic Stem Cell TransplantationCell BiologyHematologyMiddle Agedmedicine.diseaseSurgeryTransplantationSurvival RateGraft-versus-host diseaseMethotrexateHematologic NeoplasmsChronic DiseaseCyclosporineFemalebusinessImmunosuppressive AgentsBlood
researchProduct

Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated don…

2009

Graft-versus-host disease (GVHD) is a major cause of morbidity and mortality after allogeneic haematopoietic cell transplantation from unrelated donors. Anti-T-cell globulins (ATGs) might lower the incidence of GVHD. We did a prospective, randomised, multicentre, open-label, phase 3 trial to compare standard GVHD prophylaxis with ciclosporin and methotrexate with or without anti-Jurkat ATG-Fresenius (ATG-F).Between May 26, 2003, and Feb 8, 2007, 202 patients with haematological malignancies were centrally randomly assigned using computer-generated centre-stratified block randomisation between treatment groups receiving ciclosporin and methotrexate with or without additional ATG-F. One patie…

AdultMalemedicine.medical_specialtyTransplantation ConditioningAdolescentmedicine.medical_treatmentT-LymphocytesGraft vs Host DiseaseHematopoietic stem cell transplantationGastroenterologyInternal medicinemedicineHumansTransplantation HomologousCumulative incidenceProspective StudiesAntilymphocyte Serumbusiness.industryHazard ratioHematopoietic Stem Cell TransplantationMiddle AgedCiclosporinmedicine.diseaseSurvival AnalysisAnti-thymocyte globulinSurgeryTransplantationGraft-versus-host diseaseMethotrexateOncologyHematologic NeoplasmsCyclosporineRegression AnalysisDrug Therapy CombinationFemaleTransplantation ConditioningbusinessImmunosuppressive Agentsmedicine.drugThe Lancet. Oncology
researchProduct

High Cryptosporidium prevalences in healthy Aymara children from the northern Bolivian Altiplano.

1998

The prevalence of Cryptosporidium infection was determined in four Aymara communities in the Bolivian Altiplano, between the city of La Paz and Lake Titicaca, at an altitude of 3,800-4,200 meters. Single stool specimens were randomly collected from 377 5-19-year-old students, all apparently asymptomatic. The total prevalence (31.6%) is possibly the highest reported among healthy humans (a maximum of 9.8% and 2.0% in coprologic surveys in underdeveloped and developed countries, respectively) and one of the highest even in symptomatic subjects. No significant age and sex differences were observed. Such an infection prevalence is probably related to the poor sanitation conditions, contaminated…

AdultMalemedicine.medical_specialtyVeterinary medicineBoliviaSanitationAdolescentCryptosporidiosisAsymptomaticFecesSex FactorsWater SupplyVirologyEpidemiologymedicinePrevalenceAnimalsHumansSanitationChildFecesbiologyPublic healthAge FactorsCryptosporidiumOvercrowdingbiology.organism_classificationInfectious DiseasesGeographyEl NiñoAnimals DomesticChild PreschoolParasitologyFemalemedicine.symptomDemographyThe American journal of tropical medicine and hygiene
researchProduct